Giustina G, Cerudelli B, Cimino A, Rigosa C, Rotondi A, Radaeli E
J Endocrinol Invest. 1985 Feb;8(1):19-23. doi: 10.1007/BF03350629.
The effects of short term administration of 200 MRC U of synthetic salmon calcitonin (sCT) daily on carbohydrate metabolism were investigated in 10 patients with various bone diseases, 3 of whom had type II diabetes mellitus and 3 of whom had impaired glucose tolerance. Blood glucose levels during the nocturnal postabsorptive period, blood glucose and blood insulin (IRI) levels and the ratio of the area under the insulin curve to the area under the glucose curve (AI/AG) after a mixed meal were determined before and after 15 days of treatment. The values before and after sCT treatment were not significantly different, suggesting that high doses of sCT are not diabetogenic and can be given to patients with impaired glucose tolerance or to diabetics, without any risk of deteriorating metabolic control.
对10例患有各种骨病的患者研究了每日短期给予200 MRC单位合成鲑鱼降钙素（sCT）对碳水化合物代谢的影响，其中3例患有II型糖尿病，3例葡萄糖耐量受损。在治疗15天前后，测定夜间吸收后期间的血糖水平、混合餐后的血糖和血胰岛素（IRI）水平以及胰岛素曲线下面积与葡萄糖曲线下面积之比（AI/AG）。sCT治疗前后的值无显著差异，表明高剂量sCT不会致糖尿病，可给予葡萄糖耐量受损患者或糖尿病患者，而不会有代谢控制恶化的任何风险。
